Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other financing activities (2022 - 2025)

Axsome Therapeutics' Other financing activities history spans 4 years, with the latest figure at $98000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 70.21% year-over-year to $98000.0; the TTM value through Dec 2025 reached $1.2 million, up 46.69%, while the annual FY2025 figure was $1.2 million, 46.69% up from the prior year.
  • Other financing activities for Q4 2025 was $98000.0 at Axsome Therapeutics, down from $189000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $12.4 million in Q2 2023 and bottomed at -$14.2 million in Q4 2023.
  • The 4-year median for Other financing activities is $329000.0 (2024), against an average of $667153.8.
  • The largest YoY upside for Other financing activities was 261.1% in 2023 against a maximum downside of 319.27% in 2023.
  • A 4-year view of Other financing activities shows it stood at $6.5 million in 2022, then crashed by 319.27% to -$14.2 million in 2023, then soared by 102.31% to $329000.0 in 2024, then crashed by 70.21% to $98000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Other financing activities are $98000.0 (Q4 2025), $189000.0 (Q3 2025), and $517000.0 (Q2 2025).